Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics (NASDAQ: SGMO) reported 4Q and full‑year 2025 results and business milestones on March 30, 2026. Key developments include a rolling BLA submission to the FDA for ST-920 under Accelerated Approval after positive STAAR topline eGFR data, Fast Track designation for ST-503, three STAC‑BBB capsid licenses (including Lilly), and clinical progress in neurology.
Financials: 4Q25 net loss $37.4M; FY25 net loss $122.9M; revenues $39.6M in 2025; cash $20.9M at year-end with runway into Q3 2026, subject to additional funding.
Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026. A public conference call and webcast is set for 4:30 p.m. Eastern on March 30, 2026, followed by a replay available under Events.
Participants must register to receive dial‑in numbers and a unique passcode or use a dial‑out option; the live webcast link is on the company website in Investors and Media.
Sangamo Therapeutics (NASDAQ: SGMO) advanced a rolling Biologics License Application (BLA) submission to the U.S. FDA for isaralgagene civaparvovec (ST-920) for adults with Fabry disease on March 9, 2026. Sangamo has submitted preclinical and clinical modules and previously initiated the rolling submission in December 2025.
The company also submitted an antibody assay companion diagnostic to FDA CDRH seeking PMA. The STAAR registrational study showed a positive mean annualized eGFR slope at 52 weeks, which FDA agreed may serve as an endpoint to support accelerated approval.
Sangamo (NASDAQ: SGMO) reported detailed Phase 1/2 STAAR data for isaralgagene civaparvovec (ST-920) in Fabry disease, showing a positive mean annualized eGFR slope at 52 weeks and sustained α-Gal A activity up to 4.5 years.
The company initiated a rolling BLA submission to the FDA under the Accelerated Approval pathway, and the FDA agreed that 52-week mean annualized eGFR slope can serve as a primary basis for approval.
Sangamo Therapeutics (Nasdaq: SGMO) priced an underwritten offering to raise gross proceeds of approximately $25.0 million through the sale of 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares, together with accompanying warrants to purchase 52,977,325 shares.
Combined offering prices are $0.4719 per share plus warrant and $0.4619 per pre-funded warrant plus warrant. Accompanying warrants exercise at $0.4719, become exercisable six months after issuance and expire 5.5 years from issuance. Closing expected on or about February 4, 2026.
Sangamo Therapeutics (Nasdaq: SGMO) has initiated a rolling submission of a Biological License Application (BLA) to the U.S. FDA seeking accelerated approval for isaralgagene civaparvovec (ST-920) to treat adults with Fabry disease.
The registrational STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients, and the FDA agreed that eGFR slope will serve as an endpoint to support accelerated approval. Sangamo expects to complete the BLA submission under the accelerated pathway in Q2 2026. ST-920 has received Orphan Drug, Fast Track, and RMAT designations from the FDA and regulatory recognitions from EMA and UK regulators.
Sangamo Therapeutics (NASDAQ: SGMO) announced that the U.S. FDA granted Fast Track Designation to ST-503 for the treatment of intractable pain from small fiber neuropathy (SFN).
The designation may enable more frequent FDA interactions and could make ST-503 eligible for Accelerated Approval or Priority Review if criteria are met. ST-503 is an investigational epigenetic regulator currently in the Phase 1/2 STAND study, with patient recruitment underway and first dosing expected in the coming months. Sangamo previously presented nonclinical data showing durability, potency, selectivity and a favorable safety profile in nonhuman primates.
Sangamo Therapeutics (Nasdaq: SGMO) announced the FDA has accepted its request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec (ST-920) for adults with Fabry disease.
The FDA reiterated its prior agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo said the registrational Phase 1/2 STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients and that the company plans to initiate rolling BLA submission later in Q4 2025. ST-920 holds multiple regulatory designations including Orphan Drug, Fast Track, RMAT, EMA PRIME and UK Innovative Licensing pathway.
Sangamo Therapeutics (Nasdaq: SGMO) reported Q3 2025 results and program updates on Nov 6, 2025. Key clinical highlights include detailed STAAR registrational data for isaralgagene civaparvovec (ST-920) in Fabry disease showing a positive mean annualized eGFR slope 1.965 mL/min/1.73m2/year at 52 weeks (n=32) and durability of α-Gal A activity up to 4.5 years. FDA reiterated use of eGFR slope to support an accelerated approval pathway; company preparing for a potential BLA as early as Q1 2026. Neurology updates: Phase 1/2 STAND enrollment started for ST-503 with first dosing expected in coming months; ST-506 CTA expected as early as mid-2026. Financials: Q3 net loss $34.9M, revenues $0.6M (vs $49.4M prior year), cash $29.6M as of Sept 30, 2025, with Nasdaq minimum bid extension to April 27, 2026.
Sangamo Therapeutics (NASDAQ: SGMO) announced it will release Q3 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a public conference call and webcast at 8:30 a.m. ET on November 6, 2025 to review results and provide business updates.
Participants should register in advance to receive a dial‑in number and unique passcode or use the dial‑out option; joining 10 minutes early is recommended. The live webcast link is available in the Investors and Media > Events section of the Sangamo website, and a replay will be posted after the call.